EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care

Thong Duy Vo iD

Clinical and Experimental Gastroenterology · 2026-08 · Volume 19 · 1-14

DOI: 10.2147/ceg.s618553 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Experimental Gastroenterology, 2026-08. Verfasst von Thong Duy Vo. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, reflecting the global epidemic of obesity, type 2 diabetes, and metabolic syndrome. However, MASLD is not a homogeneous condition; rather, it encompasses a broad clinical and biological spectrum ranging from simple steatosis to progressive steatohepatitis, advanced fibrosis, cirrhosis, and hepatocellular carcinoma. This heterogeneity is driven by complex interactions between metabolic dysfunction, genetic susceptibility, environmental exposures, and extrahepatic comorbidities. Recent advances have shifted the paradigm from a "one-size-fits-all" approach toward risk stratification and personalized care. Non-invasive tests (NITs), including FIB-4, transient and shear wave elastography, and novel biomarkers, have enabled scalable fibrosis assessment and prognostic stratification in real-world settings. At the same time, emerging therapies targeting metabolic pathways, inflammation, and fibrosis are paving the way for individualized treatment strategies. This review provides an updated and clinically oriented synthesis of MASLD by integrating clinical heterogeneity, phenotype-based disease trajectories, multidimensional risk stratification, and personalized management into a practical framework for precision hepatology. In addition, we summarize recent therapeutic advances, discuss current controversies and implementation challenges, and highlight future directions toward individualized care.

Schlagwörter

Stichwörter der Autor:innen

MASLDfibrosisnon-invasive testspersonalized medicineprecision hepatologyrisk stratification

Autor:innen und Institutionen

  • Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh, Vietnam.
  • Department of Gastroenterology, University Medical Center Ho Chi Minh City, Ho Chi Minh, Vietnam.

ORCID-Profile: Thong Duy Vo

Zitieren

APA

Vo, T. D. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care. Clinical and Experimental Gastroenterology, Volume 19, 1-14. https://doi.org/10.2147/ceg.s618553

Vancouver

Vo TD. Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care. Clinical and Experimental Gastroenterology. 2026;Volume 19:1-14. doi:10.2147/ceg.s618553

BibTeX
@article{Vo2026,
  author = {Vo, Thong Duy},
  title = {Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care},
  journal = {Clinical and Experimental Gastroenterology},
  year = {2026},
  volume = {Volume 19},
  pages = {1--14},
  doi = {10.2147/ceg.s618553}
}
Kostenlos starten →